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Tetrazole is a five-membered ring structure composed of four nitrogen atoms and
one carbon atom and is used as an intermediate in the synthesis of pharmaceuticals, espe-
cially cephalosporins. Tetrazole and its derivatives have been reported to possess anti-
-nociceptive (1), anti-inflammatory (2), antimicrobial (3) and anticonvulsant properties
(4, 5). Benzotriazole moiety is a versatile lead molecule in pharmaceutical development
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Eight novel 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzo[d][1,2,
3]triazoles (3a-h) have been synthesized in order to ob-
tain new compounds with potential anti-nociceptive and
anti-inflammatory activity. The titled compounds were
synthesized by the condensation of 1-[2-(1H-tetrazol-5-yl)
ethyl]-1H-benzotriazole (2) and appropriate acid chlori-
des. Compound 2 was synthesized by reacting 3-(1H-
-benzo[d][1,2,3]triazol-1-yl)propanonitrile (1) with so-
dium azide and ammonium chloride in the presence of
dimethylformamide. The synthesized compounds were
characterized by spectroscopic methods (IR, 1H NMR,
mass spectroscopy) and elemental analysis. The titled com-
pounds were evaluated for anti-nociceptive activity by the
hot plate method and the writhing response method, and
anti-inflammatory activity was evaluated by the carrage-
nean induced paw edema method. 5-(2-(1H-benzo[d][1,2,3]
triazo-1-yl)ethyl)-1H-tetrazol-1-yl)(4-aminophenyl)metha-
none (3d) and 5-(2-(1H-benzo[d][1,2,3]triazo-1-yl)ethyl)-
-1H-tetrazol-1-yl)(2-hydroxyphenyl)methanone (3g) ex-
hibited significant anti-nociceptive activity. 1-(2-(1-Tosyl-
-1H-tetrazol-5-yl)ethyl)-1H-benzo[d][1,2,3]triazole (3c) and
4,5-(2-(1H-benzo[d][1,2,3]triazo-1-yl)ethyl)-1H-tetrazol-1-yl
sulfonyl)benzenamine (3f) elicited superior anti-inflam-
matory activity compared to other synthesized compounds.




* Correspondence; e-mail: rsekaran2001in@yahoo.co.in
and has a wide range of biological activities, e.g., anti-inflammatory (6), anti-nociceptive
(7), anticonvulsant (8), antimicrobial (9), protein kinase inhibiting (10) and immunosup-
pressive activities (11). Our research was focused on incorporation of the benzotriazole
moiety into tetrazoles based upon the hypothesis that this modification would improve
efficacy, since both moieties are noted for their anti-nociceptive and anti-inflammatory
properties. Thus, a series of novel 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzo[d][1,2,3]triazoles
were synthesized and tested for their anti-nociceptive and anti-inflammatory properties.
EXPERIMENTAL
Melting points were determined using a melting point apparatus (Veego, VMP III,
India) and were not corrected. Infrared spectra were obtained on a Perkin Elmer FTIR
spectrophotometer 1600 series (Perkin Elmer, USA) using potassium bromide discs. 1H
NMR spectra were recorded on a Bruker 400 MHz spectrophotometer (Bruker, USA).
Chemical shifts are reported in parts per million (d) units relative to an internal standard
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Table I. Physical and analytical data of synthesized compounds





Elemental analysis (calcd./found, %)
C H N






































































a Molecular mass determination by mass spectral analysis (M+)
of tetramethylsilane. Mass spectra were recorded on a mass spectrometer (Jeol JMS-DX
303 (Jeol, Japan) and Finnigan MAT 8230 (Finnigan MAT, Germany). Elemental analyses
were performed on a Heraeus Carlo Erba 1108 (Elementar, USA) and the analyses were
within ± 0.4 % of theoretical values.
Synthesis of 3-(1H-Benzo[d][1,2,3]triazol-1-yl)propanonitrile (1)
Benzotriazole (50 mmol) was mixed with acrylonitrile (12.5 mL) and cooled in an
ice bath. A resorcinol crystal was added to prevent polymerization. Triton B (2 mL, 40 %
V/V) was added dropwise under shaking and a vigorous reaction was observed. It was
allowed to subside and was then refluxed on a steam bath for 2 h. The solution was cooled,
extracted with ethylene dichloride and dried over anhydrous sodium sulphate. The dried
nitrile was recrystallized from ether. The desired 3-(1H-benzo[d][1,2,3]triazol-1-yl)propa-
nonitrile (1) was obtained as a solid.
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Table II. Spectral data of synthesized compounds
Compd. IR (KBr) (cm–1) 1H NMR (DMSO-d6) (d, ppm)
1 2958 (C-H), 2254 (CN), 1456 (C-H)
2.7 (2H, t, J = 7.1 Hz, CH2), 4.4 (2H, t,
J = 7.1 Hz, CH2), 6.8–7.3 (8H, m, Ar-H).
2
3462 (N-H), 2926 (C-H), 2853 (C-H),
1639 (C=N), 1458 (C-H), 1286
(N-N=N-), 1197 (tetrazole ring)
2.8 (2H, t, J = 7.1 Hz, CH2), 4.3 (2H, t,
J = 7.1 Hz, CH2), 6.8–7.3 (8H, m, Ar-H).
3a
2930 (C-H), 1695 (C=O), 1437 (C-H),
1282 (N-N=N-), 1108 and 1138
(tetrazole ring)
2.8 (2H, t, J = 7.1 Hz, CH2), 4.3 (2H, t,
J = 7.1 Hz, CH2), 6.8–7.3 (9H, m, Ar-H)
3b
2887 (C-H), 1774 (C=O), 1576 (NO2),
1457 & 1367 (C-H), 1283 (N-N=N-),
1110 (tetrazole ring)
2.8 (2H, t, J = 7.1 Hz, CH2), 4.3 (2H, t,
J = 7.1 Hz, CH2), 6.8–8.1 (8H, m, Ar-H)
3c
2930 (C-H), 1774 (C=O), 1618 (C=N),
1457 (C-H), 1283 (N-N=N-), 1108, 1133
(tetrazole ring), 1044 (SO2)
d 2.1 (3H, s, CH3), 2.8 (2H, t, J =7.1 Hz,
CH2), 4.3 (2H, t, J = 7.1 Hz, CH2), 6.8–7.7
(8H, m, Ar-H)
3d
3464 (N-H), 2798 (C-H), 1666 (C=O),
1457 (C-H), 1301 (N-N=N-), 1105
and 1162 (tetrazole ring)
2.8 (2H, t, J = 7.1 Hz, CH2), 4.3
(2H, t, J = 7.1 Hz, CH2), 4.5 (2H, s, NH2),
6.8–7.3 (8H, m, Ar-H)
3e
3463 (N-H), 2798 (C-H), 1666 (C=O),
1486 (C-H), 1301 (N-N=N-), 1105
and 1162 (tetrazole ring)
2.8 (2H, t, J = 7.1 Hz, CH2), 4.3 (2H, t,
J = 7.1 Hz, CH2), 4.5 (2H, s, NH2), 6.8–7.7
(8H, m, Ar-H)
3f
3383 (N-H), 1434 (CH), 1282 (N-N=N),
1132 (tetrazole ring), 1031(SO2)
2.8 (2H, t, J = 7.1 Hz, CH2), 4.3 (2H, t,
J = 7.1 Hz, CH2), 4.5 (2H, s, NH2), 6.8–7.3
(8H, m, Ar-H)
3g
3372 (O-H), 1774 (C=O), 1457 (C-H),
1295 (N-N=N-), 1138 (tetrazole ring
2.1 (3H, s, CH3), 2.8 (2H, t, J = 7.1 Hz, CH2),
4.3 (2H, t, J = 7.1 Hz, CH2), 5 (1H, s, OH),
6.8–7.6 (8H, m, Ar-H)
3h
3371 (O-H), 1744 (C=O), 1458 (C-H),
1283 (N-N=N-), 1108 and 1138
(tetrazole ring)
2.1 (3H, s, CH3), 2.8 (2H, t, J = 7.1 Hz, CH2),
4.3 (2H, t, J = 7.1 Hz, CH2), 5 (1H, s, OH),
6.8–7.9 (8H, m, Ar-H)
Synthesis of 1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-benzotriazole (2)
Equimolar quantities of compound (1), sodium azide, dimethylformamide (10 mL)
and ammonium chloride were heated in an oil bath for 7 h at 125 C. The solvent was re-
moved under reduced pressure, the residue was dissolved in 100 mL of water and care-
fully acidified with concentrated hydrochloric acid to pH 2. The solution was cooled to
5 C in an ice bath. Compound 2 was recrystallized from aqueous methanol.
Synthesis of 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzo[d][1,2,3]triazoles (3a-h).
General procedure
Compound 2 was treated with an equimolar amount of aromatic acid chlorides in
10 mL of sodium bicarbonate solution (10 % m/V). The mixture was shaken vigorously
until the odor of aromatic acid chloride disappeared. The solids which separated out
were filtered and dried. Recrystallization of the dried compounds from aqueous ethanol
yielded compounds 3a-h.
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Acute toxicity study. – This involves estimation of the median lethal dose (LD50) (12),
which is the dose that will kill 50 % of the animal population within 24 h post treatment
with the test substance. All animal experiments were conducted under the conditions of
the Animal Scientific Procedures. The experimental protocol was approved by the Ani-
mal Care Review Committee of the AK College of Pharmacy, India. Groups of Swiss al-
bino mice consisted of six animals and were maintained in colony cages at 25 ± 2 °C, rela-
tive humidity of 45–55 %, under a 12 h light and dark cycle; they were fed standard ani-
mal feed and water ad libitum. They were treated intraperitoneally with different doses
of test compounds (200, 400, 600, 800, 1000 mg kg–1). The animals were then observed
for 24 h for any behavioral effects such as nervousness, excitement, dullness, in-coordi-
nation or even death. The LD50 was found to be 180 mg kg–1.
Hot plate method. – All the newly synthesized compounds were tested for anti-noci-
ceptive activity by the Eddy and Leimbach method (13). Swiss albino mice were divided
into ten groups of six mice each. One group served as control and was administered 0.5 %
(V/V) Tween 80 (0.5 mL) suspension. One group was administered the standard drug
pentazocine (Sigma, USA) intraperitoneally at a dose of 5 mg kg–1 15 minutes before the
analgesic activity evaluation. Tween 80 suspension (0.5 %, V/V) of test compounds 3a-h
was administered intraperitoneally at a dose at 18 mg kg–1 to the remaining groups 15
minutes before the analgesic activity evaluation. The reaction time in seconds was noted
for all the groups on Eddy’s hot plates before and 15 minutes after administration of test
compounds and pentazocine (Table III).
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Table III. Evaluation of anti-nociceptive activity by the hot plate method
Compd. (dose)
Reaction time (s)
before treatmenta after 15 minutesa
3a (18 mg kg–1) 3.75 ± 0.55 8.66 ± 0.37b
3b (18 mg kg–1) 3.66 ± 0.66 7.33 ± 0.42c
3c (18 mg kg–1) 4.24 ± 0.89 12.33 ± 0.55b
3d (18 mg kg–1) 3.88 ± 0.56 13.00 ± 0.34b
3e (18 mg kg–1) 4.52 ± 0.76 9.50 ± 0.43b
3f (18 mg kg–1) 3.98 ± 0.24 10.68 ± 0.88b
3g (18 mg kg–1) 2.98 ± 0.35 13.83 ± 0.34b
3h (18 mg kg–1) 4.12 ± 0.55 11.50 ± 0.42b
Control 3.32 ± 0.46 3.33 ± 0.55
Pentazocine (5 mg kg–1) 4.68 ± 0.29 13.34 ± 0.46b
Control – no synthesized compound and paracetamol.
a Mean ± SEM (n = 6).
Significant difference compared with the control: b p < 0.001, c p < 0.01.
Acetic acid induced writhing method. – The synthesized compounds were also tested
for anti-nociceptive activity by the acetic acid induced writhing method (14). The ani-
mals were divided into ten groups of six. The control group of animals was adminis-
tered 0.5 % (V/V) Tween 80 (0.5 mL) suspension. The standard drug paracetamol (Micro
Labs, India) was administered intraperitoneally at a dose of 2.5 mg kg–1. Tween 80 sus-
pension (0.5 %, V/V) of test compounds were administered intraperitoneally at a dose
of 18 mg kg–1. Twenty minutes after administration of the test compounds and a stan-
dard, all groups of mice were given the writhing agent, 3 % (V/V) aqueous acetic acid at
a dose of 2 mL kg–1 intraperitoneally. The total number of writhings produced in these
animals was counted visually for 15 minutes and the number of writhings produced in
treated groups was compared with that in the control group. The results given in Table
IV are expressed as percentage protection.
Anti-inflammatory activity. – The anti-inflammatory activity was evaluated by the
carragenean induced paw edema method (15). Albino rats of Wistar strain, weighing
100–200 g, of either sex were divided into ten groups of six animals each. The animals
were maintained under normal environmental conditions. They were fed standard feed
and water ad libitum. Tween 80 suspension (0.5 %, V/V) of test compounds was adminis-
tered intraperitoneally at a dose of 18 mg kg–1. The control group was given only 0.5 %
(V/V) Tween 80 (0.5 mL) suspension. One group was administered diclofenac sodium as
standard, intraperitoneally at a dose of 2 mg kg–1. Thirty minutes after the administra-
tion of test compounds and diclofenac sodium, paw edema was induced in albino rats
by injecting 0.1 mL of carragenean suspension (1 %, V/V in normal saline), into sub-
plantar region of the left hind paw of each rat. Tree hours after carragenean injection, the
increase in paw volume was measured with a plethysmometer. The anti-inflammatory
activity was measured in terms of percentage inhibition of edema and analyzed (Table V).
360
A. Rajasekaran and K. A. Rajagopal: Synthesis of some novel triazole derivatives as anti-nociceptive and anti-inflammatory agents,
Acta Pharm. 59 (2009) 355–364.





3a (18 mg kg–1) 28 ± 1b 58
3b (18 mg kg–1) 34 ± 1 37
3c (18 mg kg–1) 23 ± 0b 62
3d (18 mg kg–1) 16 ± 1b 70
3e (18 mg kg–1) 19 ± 1b 67
3f (18 mg kg–1) 21 ± 1b 63
3g (18 mg kg–1) 9 ± 1b 85
3h (18 mg kg–1) 14 ± 1b 72
Control 54 ± 1 –
Paracetamol (2.5 mg kg–1) 9 ± 1b 88
Control – no synthesized compound and diclofenac sodium.
a Mean ± SEM (n = 6).
Significant difference compared with the control: b p < 0.001, c p < 0.01.
Statistical analysis
Statistical analysis of the biological activity of synthesized compounds on animals
was evaluated using a one-way analysis of variance (ANOVA). In all cases, posthoc com-
parisons of the means of individual groups were performed using Tukey’s test. All val-
ues were expressed as mean ± SEM. The GraphPad Prism 3.0 version was used for statis-
tical analysis.
RESULTS AND DISCUSSION
The key intermediate 3-(1H-benzo[d][1,2,3]triazol-1-yl)propanonitrile (1) was prepa-
red by refluxing 1H-benzo[d][1,2,3]triazole with acrylonitrile and Triton B. IR spectra of
compound 1 showed intense peaks at 2254 cm–1 and confirmed the formation of nitrile
(CN). Two triplets at d 2.7 and 4.4 ppm of 1H NMR spectrum confirmed the presence of
two methylene protons and a multiplet between d 6.8 and 7.3 ppm confirmed the presence
of aromatic protons (8H) in compound 1. Further, the molecular ion recorded (m/z 172
[M+]) in the mass spectrum is also in agreement with the molecular mass of the com-
pound.
1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzotriazole (2) was synthesized by reacting
3-(1H-benzo[d][1,2,3]triazol-1-yl)propanonitrile (1) with sodium azide and ammonium
chloride in the presence of dimethylformamide. The IR spectrum of compound 2 sho-
wed disappearance of CN stretching signals of nitrile. It showed a peak for the tetrazole
ring at 1197 cm–1, –N–N=N– stretching at 1286 cm–1 and NH stretching at 3462 cm–1.
The 1H NMR spectrum of compound 2 showed two triplets for methylene protons and a
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Table V. Anti-inflammatory activity of synthesized compounds by the carragenean-induced paw edema
method
Compd. (dose) Paw volume (in mL)a Inhibition after 3 h (%)
3a (18 mg kg–1) 0.38 ± 0.02 14
3b (18 mg kg–1) 0.39 ± 0.03 11
3c (18 mg kg–1) 0.24 ± 0.04 45b
3d (18 mg kg–1) 0.36 ± 0.03 18
3e (18 mg kg–1) 0.38 ± 0.02 14
3f (18 mg kg–1) 0.23 ± 0.03 47b
3g (18 mg kg–1) 0.30 ± 0.22 32
3h (18 mg kg–1) 0.31 ± 0.32 30
Control 0.44 ± 0.19 –
Diclofenac sodium (2 mg kg–1) 0.17 ± 0.02 61b
Control – no synthesized compound and diclofenac sodium.
a Mean ± SEM (n = 6).
Significant difference compared with the control: b p < 0.01.
multiplet at d 6.8–7.3 ppm for aromatic (8H) protons. Molecular ion recorded in the mass
spectrum (m/z 215 [M+]) confirmed the assigned structure.
1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzotriazole (2) has a free secondary amino group
which can readily react with acid chlorides. Hence, the titled compounds, 1-[2-(1H-tetra-
zol-5-yl)ethyl]-1H-benzo[d][1,2,3]triazoles (3a-h), were obtained by substitution of vari-
ous aromatic carbonyl and sulphoxide moieties using aromatic acid chlorides in the pre-
sence of sodium bicarbonate solution. Formation of the titled compounds was confirmed
by the disappearance of the peak due to NH stretching of compound 2. IR spectra of all
compounds 3a-h showed the presence of peaks due to (N-N=N) and the tetrazole ring.
1H NMR spectra of all compounds 3a-h showed absorption signals at d 2.8 and 4.3 ppm
for the two methylene protons and multiplet signals between 6.8 and 7.8 ppm for the
presence of aromatic protons. Mass spectra of the titled compounds showed molecular
ion peaks corresponding to their molecular formula. Elemental analysis satisfactorily con-
firmed the elemental composition and purity of the synthesized compounds.
The results of analgesic testing indicated that the test compounds 3d and 3g exhibi-
ted significant analgesic activity after 15 min of reaction time (13 and 13.83), tested by
the hot plate method. Substitution of the amino group in 3d and hydroxyl group in 3g in
ortho position of aryl moiety increased the anti-nociceptive activity. All other com-
pounds exhibited moderate anti-nociceptive activity. With the exception of 3b, all the
compounds exhibited anti-nociceptive activity tested by the acetic acid induced writh-
ing method at a dose of 18 mg kg–1. The anti-nociceptive activity of compounds 3d, 3e,
3g and 3h was found to be superior compared to other synthesized compounds. Com-
pounds 3d and 3g were found to be the most active derivatives tested by both the hot
plate method and the acetic acid induced writhing method; they possess 2-aminoben-
zoyl and 2-hydroxybenzoyl group at the tetrazole moiety of the benztriazole framework.
Synthesized compounds 3a-h exhibited poor anti-inflammatory activity (16–22 % pro-
tection only) against carragenean induced paw edema, whereas the standard drug diclo-
fenac sodium (Novartis Laboratories, India) showed 61 % inhibition under similar condi-
tions. Among the compounds tested, compounds 3c and 3f exhibited mild anti-inflam-
matory activity. Inclusion of substituted benzoyl moiety in the tetrazole moiety of ben-
zotriazole framework did not produce any marked inhibition of edema. However, inclu-
sion of substituted sulfonyl moiety in 3f resulted in mild anti-inflammatory properties.
CONCLUSIONS
In the present study, synthesis of a new series of 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-
-benzo[d][1,2,3]triazoles (3a-h) has been described. Compounds 3d and 3g were found to
be the most active derivatives with promising anti-nociceptive activity. We can deduce
from the results that replacement of active hydrogen from the tetrazole moiety with sub-
stituted benzoyl and sulfonyl moiety can create potent anti-nociceptive compounds,
whereas replacement of active hydrogen from the tetrazole moiety with substituted
sulfonyl moiety may lead to mild anti-inflammatory activity. Further studies on struc-
tural modifications are needed to increase the anti-inflammatory activity.
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S A @ E T A K
Sinteza novih derivata triazola kao anti-nociceptivnih i protuuaplnih agenasa
AIYALU RAJASEKARAN i KALASALINGAM ANANDA RAJAGOPAL
Sintetizirano je osam novih 1-[2-(1H-tetrazol-5-il)etil]-1H-benzo[d][1,2,3]triazola (3a-h) s
potencijalnim anti-nociceptivnim i protuupalnim djelovanjem. Navedeni spojevi pri-
pravljeni su kondenzacijom 1-[2-(1H-tetrazol-5-il)etil]-1H-benzotriazola (2) i odgovaraju-
}ih kiselinskih klorida. Spoj 2 dobiven je reakcijom 3-(1H-benzo[d][1,2,3]triazol-1-il)pro-
panonitrila (1) s natrijevim azidom i amonijevim kloridom u prisutnosti dimetilformamida.
Sintetizirani spojevi su karakterizirani spektroskopskim metodama (IR, 1H NMR, spek-
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troskopijom masa) i elementarnom analizom. Anti-nociceptivno djelovanje ispitivano je
metodom vru}e plo~e i pra}enjem odgovora na bolne podra`aje, dok je protuupalno dje-
lovanje evaluirano testom s karageninom. 5-(2-(1H-benzo[d][1,2,3]triazo-1-il)etil)-1H-te-
trazol-1-il)(4-aminofenil)metanon (3d) i 5-(2-(1H-benzo[d][1,2,3]triazo-1-il)etil)-1H-tetra-
zol-1-il) (2-hidroksifenil)metanon (3g) pokazali su zna~ajno anti-nociceptivno djelovanje.
1-(2-(1-Tosil-1H-tetrazol-5-il)etil)-1H-benzo[d][1,2,3]triazol (3c) i 4-5-(2-(1H-benzo[d][1,2,
3]triazo-1-il)etil)-1H-tetrazol-1-il sulfonil)benzenamin (3f) pokazali su superiorno protu-
upalno djelovanje u odnosu na druge sintetizirane spojeve. Daljnja istra`ivanja su nu`na
kako bi se razjasnio mehanizam djelovanja.
Klju~ne rije~i: sinteza, 1-[2-(1H-tetrazol-5-il)etil]-1H-benzo[d][1,2,3]triazol, nocicepcija, upala
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